Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations of topical sofpironium, which has been shown to be partially metabolized by the isoenzyme. In a pharmacokinetic study in patients with primary axillary hyperhidrosis, sofpironium systemic exposure (AUC) and peak plasma concentration (Cmax) increased approximately 2-fold following concomitant use with the potent CYP450 2D6 inhibitor paroxetine at a 20 mg oral dose. Clinical data for sofpironium use in combination with other less potent CYP450 2D6 inhibitors are not available.

MANAGEMENT: Caution is advised when sofpironium topical is used concurrently with CYP450 2D6 inhibitors. Patients should be more closely monitored for adverse effects such as blurred vision, urinary retention, difficulty controlling body temperature in warm environments, and dry mouth.

You may experience reduced absorption of halofantrine in the presence of food. Halofantrine should be taken on an empty stomach at least 1 hour before or 2 hours after food. This will make it easier for your body to absorb the medication. Also, while taking halofantrine, you should avoid grapefruits and grapefruit juice. Grapefruit can raise the levels of halofantrine in your body and lead to increased adverse effects. Do not increase or decrease the amount of grapefruit products in your diet without first talking to your doctor.